This page shows the latest Jazz Pharma news and features for those working in and with pharma, biotech and healthcare.
Drug combination failed to improve overall survival rate. Jazz Pharmaceuticals and PharmaMar have revealed that their small cell lung cancer (SCLC) therapy lurbinectedin has failed to meet the primary endpoint in ... Jazz licensed lurbinectedin from
UK-based Redx Pharma has signed a research collaboration with Jazz Pharmaceuticals focused on discovering and developing drug candidates for two new cancer targets. ... We look forward to collaborating with Jazz on new targeted therapies for patients who
Iain McGill. Iain McGill has been recruited from his role as senior vice president Europe and Rest of World for Jazz Pharmaceuticals, the specialist pharma company, best known in Europe for ... He was part of the management team which
The latest from pharma, biotech and healthcare. Jazz Pharma gains EU approval for niche AML treatment. ... or AML with myelodysplasia-related changes,” said Daniel Swisher, president and chief operating officer at Jazz Pharmaceuticals.
The US FDA has given the green light for Jazz Pharma's Defitelio, adding another product to the company's stable of rare disease therapies. ... Jazz acquired Defitelio as part of its $1bn purchase of Italy's Gentium in 2013.
disease therapy sector, with suggestions Shire or Jazz Pharma may be interested in the unit.
More from news
Approximately 1 fully matching, plus 10 partially matching documents found.
$11m. Servier. Sorrento. $821m. $28m. Jazz Pharma. Pfenex. $181m. $15m. ONO Pharma. ... Sprint BioScience/ Petre Pharma. PIP4K2a inhibitor programme. Licence. 240. Pfenex/ Jazz Pharmaceuticals.
The other deal of interest is the re-emergence of EUSA Pharma with products acquired from Jazz Pharmaceuticals. ... investor, Essex Woodlands, has bought back products worth $27m and the EUSA Pharma name from Jazz for an undisclosed amount.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
EUSA's new CEO Morley comes to the company from Jazz, where he was vice president, head of commercial for Europe and International Markets, with responsibility for the original EUSA Pharma ... business. Prior to his time with Jazz, and before that the pre
This company was later sold to Jazz Pharma in 2012 for $700m. ... Prior to founding EUSA in 2005, Morton founded Zeneus Pharma in 2003, before selling the company to Cephalon for $360m.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...